Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Aug 31, 2022
NEW YORK , Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
Aug 02, 2022
NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

View HTML
UPLOAD

UPLOAD

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML
UPLOAD

UPLOAD

View HTML

Data provided by Kaleidoscope.

Events and Presentations
Corporate Presentation